We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Urine Test Could Predict Outcome of Cartilage Transplant Surgery

By LabMedica International staff writers
Posted on 18 Sep 2025

Cartilage transplant surgery provides an alternative to artificial joint replacements by using donor tissue to restore knee function. More...

While many patients benefit, outcomes can vary, leaving uncertainty about who is most likely to succeed. Now, new research has revealed that urine samples contain protein biomarkers that may help predict surgical results, offering a noninvasive way to guide treatment decisions before performing any invasive procedures.

A team of researchers at the University of Missouri (Columbia, MO, USA) has been investigating biological markers to predict the outcomes of osteochondral allograft transplantation, a knee procedure that replaces damaged cartilage with healthy donor tissue. This approach preserves the patient’s natural joint rather than relying on artificial materials. The team analyzed protein biomarkers in urine, which fluctuate with age and other factors, making them dynamic indicators for surgical candidacy that can change over time.

The study identified nine proteins strongly associated with poor outcomes after surgery. Patients with elevated levels of these proteins were significantly less likely to experience success with the transplant. The findings, published in The Journal of Knee Surgery, demonstrate the potential for urine-based biomarker testing to guide patient selection and improve precision in orthopedic medicine.

This discovery could empower patients and clinicians to make more informed choices about the timing and type of knee surgery. Because biomarker levels are not fixed, patients who are not initially good candidates may later qualify, enabling flexible and personalized care. The research marks a shift from optimizing the surgery itself to optimizing the patient for surgery, laying the groundwork for more tailored orthopedic solutions.

“We’ve spent 15 years focused on optimizing the surgery for the patient, and now we are focusing on optimizing the patient for the surgery. These protein biomarkers give us important clues as to who can best benefit from this particular surgery,” said Jimi Cook, DVM ‘94, PhD ‘98, who led the research team. “By better understanding which protein biomarkers are linked with unsuccessful outcomes, we can determine the best data-driven treatment plan for each individual with knee pain before doing any invasive procedures.”

Related Links:
University of Missouri


New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.